
Dr Marc Hoffman is a pharmaceutical physician with more than 35 years of experience in roles of increasing responsibility. As a Chief Medical Officer for several organizations, he has led clinical development, medical affairs, and pharmacovigilance teams as well as fully integrated, cross-functional units within a business. Dr Hoffman brings broad perspective to these roles, having worked on both the sponsor (pharma) and service (CRO) sides of the business which provides unique insights into the drug development and outsourcing paradigm. With experience that spans more than three decades, in almost every therapeutic area imaginable (from IND thru NDA and beyond, working in more than 40 countries), Dr Hoffman brings a versatility to these roles and is able to quickly immerse himself in challenges across the development spectrum.

Additionally, he has led R&D organizations, driving prioritization and focus in the early lifecycle development of products and has helped numerous clients to define the potential of their asset in the build and adjudication of full clinical development programs. This involved go/no-go clinical and commercial decision points to include working in concert with commercial partners, prioritizing the market opportunity and the commercial aspect of launch and life-cycle management.

Prior to joining MedSurgPI, Dr. Hoffman was CMO at Rockwell Medical, a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Prior to joining Rockwell, he was CMO at Celerion and CMO and Senior Vice-President & General Manager, Pharmaceutical Development at Theorem Clinical Research, two leading midsized CROs. Prior to joining Theorem, he was Vice President, Global Medical Affairs and Product Safety at Hospira and held several leadership roles at Baxter Healthcare including Vice President, Global Regulatory Affairs and Medical Vigilance Americas & Asia and Vice President, Clinical Research and Medical Affairs in their Anesthesia, Critical Care and Oncology (ACCO) business unit.